Literature DB >> 26361959

Regulation of β-catenin transcription activity by leupaxin in hepatocellular carcinoma.

Jia Shi1, Wen-Jie Wu1, Gang Hu2, Xin Yu2, Ge-Shu Yu2, Han Lu3, Ming-Liang Yang4, Bin Liu5, Zhi-Xiang Wu6.   

Abstract

In human cancers, β-catenin is accumulated in the nucleus and activates mRNA transcription of many oncogenic genes, such as cyclin D1 and c-myc. However, the mechanism of β-catenin-mediated transcriptional activation remains largely unknown. In the present study, we identified leupaxin, an adaptor protein sharing homology with the focal adhesion protein, as a novel coactivator for β-catenin in human hepatocellular carcinoma (HCC). We show that leupaxin could interact with β-catenin and enhance its transcriptional activity through recruitment of coactivator complex, including steroid receptor coactivator 1 (SRC-1) and P300. As a result, leupaxin regulates HCC cell proliferation and cell-cycle progression in the presence of intact Wnt/β-catenin signaling. Furthermore, leupaxin is overexpressed in HCC tissues and correlated with mRNA levels of cyclin D1 and c-myc. Therefore, this is the first demonstration of a role for the leupaxin in the regulation of HCC progression, at least in part, by enhancing β-catenin transcription activity.

Entities:  

Keywords:  Coactivator; Hepatocellular carcinoma (HCC); Leupaxin; Transcription activity; β-catenin

Mesh:

Substances:

Year:  2015        PMID: 26361959     DOI: 10.1007/s13277-015-4060-4

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  24 in total

1.  Synergy between tumor suppressor APC and the beta-catenin-Tcf4 target Tcf1.

Authors:  J Roose; G Huls; M van Beest; P Moerer; K van der Horn; R Goldschmeding; T Logtenberg; H Clevers
Journal:  Science       Date:  1999-09-17       Impact factor: 47.728

Review 2.  Transcription factors as targets for cancer therapy.

Authors:  James E Darnell
Journal:  Nat Rev Cancer       Date:  2002-10       Impact factor: 60.716

Review 3.  The Wnt/β-catenin pathway in ovarian cancer: a review.

Authors:  Rebecca C Arend; Angelina I Londoño-Joshi; J Michael Straughn; Donald J Buchsbaum
Journal:  Gynecol Oncol       Date:  2013-10-11       Impact factor: 5.482

4.  Leupaxin is a novel LIM domain protein that forms a complex with PYK2.

Authors:  B P Lipsky; C R Beals; D E Staunton
Journal:  J Biol Chem       Date:  1998-05-08       Impact factor: 5.157

5.  Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells.

Authors:  O Tetsu; F McCormick
Journal:  Nature       Date:  1999-04-01       Impact factor: 49.962

6.  The chromatin-remodeling enzyme BRG1 modulates vascular Wnt signaling at two levels.

Authors:  Courtney T Griffin; Carol D Curtis; Reema B Davis; Vijay Muthukumar; Terry Magnuson
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-24       Impact factor: 11.205

Review 7.  WNT and beta-catenin signalling: diseases and therapies.

Authors:  Randall T Moon; Aimee D Kohn; Giancarlo V De Ferrari; Ajamete Kaykas
Journal:  Nat Rev Genet       Date:  2004-09       Impact factor: 53.242

8.  Wilms tumor suppressor WTX negatively regulates WNT/beta-catenin signaling.

Authors:  Michael B Major; Nathan D Camp; Jason D Berndt; Xianhua Yi; Seth J Goldenberg; Charlotte Hubbert; Travis L Biechele; Anne-Claude Gingras; Ning Zheng; Michael J Maccoss; Stephane Angers; Randall T Moon
Journal:  Science       Date:  2007-05-18       Impact factor: 47.728

9.  Leupaxin stimulates adhesion and migration of prostate cancer cells through modulation of the phosphorylation status of the actin-binding protein caldesmon.

Authors:  Sascha Dierks; Sandra von Hardenberg; Thomas Schmidt; Felix Bremmer; Peter Burfeind; Silke Kaulfuß
Journal:  Oncotarget       Date:  2015-05-30

10.  Leupaxin is expressed in mammary carcinoma and acts as a transcriptional activator of the estrogen receptor α.

Authors:  Silke Kaulfuss; Anna-Maria Herr; Anja Büchner; Bernhard Hemmerlein; Andreas R Günthert; Peter Burfeind
Journal:  Int J Oncol       Date:  2015-05-06       Impact factor: 5.650

View more
  6 in total

1.  [Small interfering RNA-mediated LPXN silencing suppresses proliferation and enhances drug sensitivity of human acute monocytic leukemia SHI-1 cells in vitro].

Authors:  Guohua Zhu; Haiping Dai; Yuanxun Duan; Zelin Yu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-07-30

2.  Expression of microRNAs in tumors of the central nervous system in pediatric patients in México.

Authors:  Pilar Eguía-Aguilar; Lisette Gutiérrez-Castillo; Mario Pérezpeña-Díazconti; Jeanette García-Chéquer; Jorge García-Quintana; Fernando Chico-Ponce de León; Luis Gordillo-Domínguez; Samuel Torres-García; Francisco Arenas-Huertero
Journal:  Childs Nerv Syst       Date:  2017-08-16       Impact factor: 1.475

3.  RNAi screening identifies a mechanosensitive ROCK-JAK2-STAT3 network central to myofibroblast activation.

Authors:  Raymond S Oh; Andrew J Haak; Karry M J Smith; Giovanni Ligresti; Kyoung Moo Choi; Tiao Xie; Shaohua Wang; Paula R Walters; Michael A Thompson; Michelle R Freeman; Logan J Manlove; Vivian M Chu; Carol Feghali-Bostwick; Anja C Roden; Jürgen Schymeinsky; Christina M Pabelick; Y S Prakash; Robert Vassallo; Daniel J Tschumperlin
Journal:  J Cell Sci       Date:  2018-05-15       Impact factor: 5.285

Review 4.  Paxillin actions in the nucleus.

Authors:  Xiaoting Ma; Stephen R Hammes
Journal:  Steroids       Date:  2017-10-31       Impact factor: 2.668

5.  Overexpression and Activation of αvβ3 Integrin Differentially Affects TGFβ2 Signaling in Human Trabecular Meshwork Cells.

Authors:  Mark S Filla; Kristy K Meyer; Jennifer A Faralli; Donna M Peters
Journal:  Cells       Date:  2021-07-29       Impact factor: 6.600

Review 6.  Omics Approaches to Identify Potential Biomarkers of Inflammatory Diseases in the Focal Adhesion Complex.

Authors:  Johanne Brooks; Alastair Watson; Tamas Korcsmaros
Journal:  Genomics Proteomics Bioinformatics       Date:  2017-04-01       Impact factor: 7.691

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.